Secretion of GIP in responders to acarbose in obese Type 2(NIDDM) patients

Journal of Diabetes and its Complications

Volumn 15, Issue 5, 2001, Pages 245-249

  Takei, Izumi ^b   Miyamoto, Kazunori ^a   Funae, Osamu ^a   Ohashi, Norimi ^a   Meguro, Syu ^a   Tokui, Mikiya ^a   Saruta, Takao ^a  

^a KEIO UNIVERSITY   (Japan)

^b BAYER YAKUHIN LTD   (Japan)

Author keywords

Acarbose; GIP; Leptin; Obesity; Type 2 diabetes

Indexed keywords

ACARBOSE; CHOLECYSTOKININ; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; HEMOGLOBIN A1C; LEPTIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPOTHESIS; INSULIN RESISTANCE; JAPAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; WEIGHT REDUCTION;

ACARBOSE; AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; HORMONES; HUMANS; LEPTIN; LIPIDS; MALE; MIDDLE AGED; OBESITY; POSTPRANDIAL PERIOD;

EID: 0034868915     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(01)00148-9     Document Type: Article

References (19)

1. Recent advances in the pharmacological control of energy balance and body weight
2. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus
3. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential
4. Multicenter: placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus
5. Serum immunoreactive leptin concentrations in normal weight and obese humans
6. Clinical experience with acarbose as first line therapy in NIDDM
7. Effects of acarbose on the relationship between changes in GIP and insulin responses to meals in normal subjects
8. Glibenclamide, but not acarbose, increases leptin concentrations parallel to changes in insulin in subjects with NIDDM
9. Therapeutic potential of acarbose as first line drug in NIDDM insufficiently treated with diet alone
10. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients
11. Acarbose in the treatment of type 1 diabetes
12. Acarbose for treatment of type II diabetes: the results of a Canadian multi-center trial
13. Clinical application of a glucoside-hydrolase inhibitor (Bay g 5421) to patients with hyperlipidemia and maturity onset type diabetes mellitus
14. Efficacy and safety of acarbose in the treatment of type 2 diabetes: data from a 2-year surveillance study
15. Acarbose treatment in insulin-dependent (type I) diabetes mellitus
16. Effects of acarbose (Glucobay) in persons with type 1 diabetes: a multicentre study
17. Effects of acarbose on fecal microflora of hyperlipidemic patients
18. The use of acarbose in the primary-care setting: evaluation of efficacy and tolerability of acarbose by postmarking surveillance study
19. Long-term effects of intestinal alpha-glucosidase inhibition on postprandial glucose, pancreatic and gut hormone responses and fasting serum lipids in diabetics on sulphonylureas